People: Valeant Pharmaceuticals International Inc (BVF.BE)

BVF.BE on Berlin Stock Exchange

57.55EUR
24 May 2013
Price Change (% chg)

€-0.71 (-1.22%)
Prev Close
€58.71
Open
€57.55
Day's High
€57.55
Day's Low
€57.55
Volume
--
Avg. Vol
69
52-wk High
€60.61
52-wk Low
€34.81

Search Stocks

Summary

Name Age Since Current Position

J. Michael Pearson

 53 2011 Chairman of the Board, Chief Executive Officer

Howard Schiller

 2012 Chief Financial Officer, Executive Vice President, Director

Robert Chai-Onn

 42 2012 Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development

Laizer Kornwasser

 2013 Executive Vice President, Company Group Chairman

Brian Stolz

 37 2011 Executive Vice President - Administration, Chief Human Capital Officer

Ryan Weldon

 35 2012 Executive Vice President, Company Group Chairman

Susan Hall

 53 2012 Senior Vice President, Global Head - Research and Development

Robert Ingram

 70 2011 Lead Independent Director

Ronald Farmer

 62 2011 Independent Director

Theo Melas-Kyriazi

 53 2010 Independent Director

G. Mason Morfit

 37 2010 Independent Director

Robert Power

 56 2008 Independent Director

Norma Provencio

 55 2010 Independent Director

Lloyd Segal

 49 2007 Independent Director

Katharine Stevenson

 50 2010 Independent Director

Laurie Little

 Vice President - Investor Relations
» Insider Trading

Biographies

Name Description

J. Michael Pearson

 Mr. J. Michael Pearson is Chairman of the Board, Chief Executive Officer of Valeant Pharmaceuticals International Inc. Mr. Pearson has been the CEO of the Company and serving on the Board since September 2010 and the Chairman of the Board since March 2011. From February 2008 to September 2010, he was the chairman of the board and CEO of VPI before the Merger. Prior to that, Mr. Pearson served on McKinsey’s board of directors until he left to join VPI. He joined McKinsey in 1984, and over a 23-year career, he worked with CEOs and was an integral driver of turnarounds, acquisitions, and corporate strategy. Within McKinsey, Mr. Pearson held various positions, including head of its global pharmaceutical practice and head of its mid-Atlantic region.

Howard Schiller

 Mr. Howard Bradley Schiller is Chief Financial Officer, Executive Vice President, Director of Valeant Pharmaceuticals International Inc. Mr. Schiller been the Chief Financial Officer (“CFO”) of the Company since December 2011 and has been serving on the Board of the Company since September 2012. Mr. Schiller joined the Company following a 24-year career at Goldman Sachs, a global investment banking firm. From 2009 to 2010, Mr. Schiller was the chief operating officer for the Investment Banking Division of Goldman Sachs, responsible for the management and strategy of the business. From 2003 to 2009, he was responsible for the global healthcare, consumer products, retail, industrial and natural resource businesses in the Investment Banking Division of Goldman Sachs. During his 24 years at Goldman Sachs, he advised multinational companies on strategic transactions, financings, restructuring and leveraged buyouts.

Robert Chai-Onn

 Mr. Robert Roswell Chai-Onn is Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development of Valeant Pharmaceuticals International Inc. He has been Executive Vice President, General Counsel and Corporate Secretary since September 2010 and effective March 28, 2012 he became Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development. From 2004 to September 2010, Mr. Chai-Onn was Vice President, Assistant General Counsel at VPI. He has been instrumental in the Company’s strategic transactions, including the Merger. Prior to 2004, Mr. Chai-Onn was a corporate lawyer at the law firm of Gibson, Dunn & Crutcher LLP, where he performed a variety of corporate, mergers and acquisitions and financial legal work.

Laizer Kornwasser

 Mr. Laizer D. Kornwasser has been appointed as Executive Vice President, Company Group Chairman of Valeant Pharmaceuticals International Inc., effective February 1, 2013. He was a Senior Executive at Medco Health prior to its acquisition by Express Scripts. At Medco he reported directly into the CEO and was a member of Executive Committee. He served as Senior Vice President, Consumer Solutions and Retail Markets and was responsible for retail network and mail pharmacy products and strategy. He oversaw network pricing, negotiations, plan designs and programs that maximized the retail and mail channels. Mr. Kornwasser was also responsible for the integrated care solution for Medco's six million members with diabetes. Mr. Kornwasser joined Medco in August 2003, and was initially responsible for building a business development team, post spin-off from Merck. In this role he oversaw all acquisitions, joint ventures and was actively involved in developing the company's long-term growth strategy. He later assumed responsibility for the companies' channel and generic drug strategy and was President of its diabetes division, which focused on direct to consumer solutions. Prior to joining Medco, Mr. Kornwasser held positions at Merrill Lynch and Coopers & Lybrand, and served as an associate professor at Yeshiva University. He has an MBA from Harvard Business School and a BS in Accounting from Yeshiva University.

Brian Stolz

 Mr. Brian M. Stolz is Executive Vice President - Administration, Chief Human Capital Officer of Valeant Pharmaceuticals International, Inc., since June 2011. Prior to joining the Company, from February 2009 through June 2011, Mr. Stolz was a Principal at ghSMART, a leadership consulting and advisory firm where he worked with corporate and alternative investment clients on human resource issues. In this role, he assessed and trained C-Level executives and professionals, created and implemented hiring and performance evaluation processes and advised boards and investment committees on senior-level hires. Prior to joining ghSMART, from November 2007 to December 2008, Mr. Stolz was a consultant at McKinsey and was a member of the McKinsey Pharmaceuticals and Medical Products group.

Ryan Weldon

 Mr. Ryan Weldon has been Executive Vice President, Company Group Chairman of Valeant Pharmaceuticals International Inc., since December 2012. He served as Vice President & General Manager, Aesthetics from December 2011 to December 2012 and Vice President & General Manager, Neurology & Other from January 2010 to December 2011. He joined VPI in September 2008 and had held roles of Senior Director, Neurology and Director, Epilepsy at VPI.

Susan Hall

 Dr. Susan T. Hall is Senior Vice President, Global Head - Research and Development of Valeant Pharmaceuticals International, Inc., since February 2012. Before joining VPI in 2006 as Vice President, Global Regulatory Science and Compliance, she was with GSK, initially in the U.K. and then in the U.S., where she held various management and leadership positions within the disciplines of Clinical Pharmacology, Project Management, Medical Affairs, Genomics and Regulatory Affairs.

Robert Ingram

 Mr. Robert A. Ingram is Lead Independent Director of Valeant Pharmaceuticals International Inc. Mr. Ingram has been serving on the Board of the Company since September 2010, was the Lead Director from September 2010 to December 2010, was the Chairman of the Board from December 2010 to March 2011. Since January 2007, Mr. Ingram has been a general partner at Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. Since January 2010, he has served as a special advisor to the Chief Executive Officer (“CEO”) of GlaxoSmithKline (“GSK”). He served as Vice Chairman Pharmaceuticals of GSK from 2002 through 2009 and Chief Operating Officer and President of Pharmaceutical Operations, CEO of Glaxo Wellcome plc from October 1997 to December 2000 and chairman of the board of Glaxo Wellcome Inc., Glaxo Wellcome plc’s U.S. subsidiary, from January 1999 to December 2000. Mr. Ingram was President and CEO of Glaxo Wellcome Inc. from October 1997 to January 1999. Mr. Ingram is also a member of the Board of Advisors for the H. Lee Moffitt Cancer Center and Research Triangle Institute, as well as Chairman of the Board, Research Triangle Foundation of North Carolina and Glaxo North Carolina Foundation. Mr. Ingram currently serves on the boards of Edwards Life Sciences Corporation (member of compensation committee); CREE, Inc. (lead director, member of compensation committee and governance and nominations committee); and Elan Corporation, plc (chairman of the board). He is a former director of Allergan Inc., Misys plc, Nortel Networks Corporation (“Nortel”), Wachovia Corporation, OSI Pharmaceuticals, Inc., Lowe’s Companies, Pharmaceuticals Product Development Inc, and Valeant Pharmaceuticals International (“VPI”), which was merged into the Company, then known as Biovail Corporation, in September 2010 (the “Merger”) at which time the Company changed its name to Valeant Pharmaceuticals International, Inc.

Ronald Farmer

 Mr. Ronald Harold Farmer is Independent Director of Valeant Pharmaceuticals International, Inc., since August 2011. Since 2003, Mr. Farmer has been the Managing Director of Mosaic Capital Partners, a Toronto-based holding company with interests in several private companies in Canada and the United States. Mr. Farmer is also Director Emeritus of McKinsey & Company (“McKinsey”) where he spent 25 years in the Toronto and New York offices prior to his retirement in 2003. At McKinsey, he worked with global corporations in a variety of industries on strategy and organization challenges and held a number of leadership positions, including serving as a Managing Partner of the Canadian practice from 1991 to 1997 and its Global eBusiness practice. He served on McKinsey’s Shareholder Council (board of directors). Mr. Farmer is a director on several private company boards including Integran Technologies and PowerMetal Technologies. He has also been a director of the Bank of Montreal since 2003 where he serves on the audit, nominating and governance, and human resources committees. He also serves on the Advisory Council of the Schulich School of Business. He is a former director of Afexa Life Sciences Inc.

Theo Melas-Kyriazi

 Mr. Theo Melas-Kyriazi is Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. He has been the Chief Financial Officer of Levitronix Technologies LLC, magnetically levitated bearingless motor technology, since 2011, and served as the Chief Financial Officer of its affiliate, Levitronix LLC since 2006. He was the Chief Financial Officer of Thermo Electron Corporation from January 1999 through October 2004. Mr. Melas-Kyriazi was a Vice President of Thermo Electron Corporation during 1998, in charge of corporate strategy; he served as the CEO of Thermo Spectra Corporation, a publicly-traded majority-owned subsidiary of Thermo Electron, from 1994 to 1998, and was Treasurer of Thermo Electron Corporation and all of its publicly traded subsidiaries from 1988 to 1994. Mr. Melas-Kyriazi is a former director of VPI, Helicos BioSciences Corporation, Cyberkinetics Neurotechnology Systems, Inc. and Glenrose Instruments Inc.

G. Mason Morfit

 Mr. G. Mason Morfit is Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. He is currently a partner and a member of the Management Committee of ValueAct Capital, a privately owned investment firm. Prior to joining ValueAct Capital in January 2001, Mr. Morfit worked in equity research for Credit Suisse First Boston for more than two years, where he supported the senior healthcare services analyst, covering fifteen companies in the managed care and physician services industries. He is also a CFA charterholder. Mr. Morfit currently serves on the board of C.R. Bard, Inc. He is a former director of VPI, Afexa Life Sciences Inc., Immucor, Inc., Advanced Medical Optics, Inc., MSD Performance, Inc. and Solexa, Inc.

Robert Power

 Mr. Robert N. Power is Independent Director of Valeant Pharmaceuticals International Inc., since August 2008. Mr. Power was a faculty member at The Wharton School of Business, University of Pennsylvania, where he taught multinational marketing from 2009 to 2011. Mr. Power has over 25 years’ experience working in the pharmaceutical and biotechnology industry through a number of leadership positions with Wyeth beginning in 1985 through 2007, including Director — New Product Development, Managing Director — U.K./Ireland, Vice President — Global Marketing, President — Europe, Middle East, Africa, President — International and Executive Vice President — Global Business Operations. Mr. Power also has completed the Director Professionalism course offered by the National Association of Corporate Directors.

Norma Provencio

 Ms. Norma A. Provencio is Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. She has been president and owner of Provencio Advisory Services, Inc., a healthcare financial and operational consulting firm, since October 2003. From May 2002 to September 2003, she was Partner-in-Charge of the Healthcare Industry for the Pacific Southwest for KPMG LLP. From 1979 to May 2002, she was with Arthur Andersen, and was Partner-in-Charge of Arthur Andersen’s Pharmaceutical, Biomedical and Healthcare Practice for the Pacific Southwest from November 1995 to May 2002. Ms. Provencio is currently a member of the Board of Regents of Loyola Marymount University and on the board of Beazer Homes (chair of audit committee and member of compensation committee). In addition, Ms. Provencio is a former director of VPI, International Aluminum Corporation and Signalife, Inc.

Lloyd Segal

 Mr. Lloyd M. Segal is Independent Director of Valeant Pharmaceuticals International Inc., since December 2007. Since February 2010, Mr. Segal has been a General Partner at Persistence Capital Partners, a healthcare focused private equity fund. From 1998 to 2008, he served as President and CEO of Caprion Pharmaceuticals which became Thallion Pharmaceuticals, Inc. in 2007, where he still serves as chairman of the board. He was previously a management consultant with McKinsey and President and CEO of Advanced Bioconcept Ltd. Mr. Segal currently serves on the board of Thallion Pharmaceuticals, Inc. and GBC American Growth Fund, Inc. and on the Advisory Council of the School of Science at Brandeis University.

Katharine Stevenson

 Ms. Katharine B. Stevenson is Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. Ms. Stevenson is a Corporate Director who serves on a variety of corporate and not-for-profit boards. She was formerly a senior executive of Nortel from 1995-2007 and has over 20 years of experience as a senior financial executive in Canada and the United States. Ms. Stevenson was responsible for all treasury activity at Nortel, including global treasury operations, corporate and structured finance, credit, and risk management. Prior to joining Nortel, Ms. Stevenson held various progressively senior finance roles at J.P. Morgan & Company, Inc. She was with J.P. Morgan from 1984 to 1995. Ms. Stevenson is currently a member of the board of directors of CAE Inc. (member of audit committee), Open Text Corporation (member of audit committee) and the Canadian Imperial Bank of Commerce (member of risk management committee). She formerly was a director of Afexa Life Sciences, Inc. and OSI Pharmaceuticals Inc. Ms. Stevenson is also a past Chair and Governor of The Bishop Strachan School and a Vice Chair and Governor of the University of Guelph. She has received her ICD.D, the professional designation for directors in Canada.

Laurie Little

Insider Trading

» Full list on Insider Trading
Search Stocks